{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-073558","form_type":"8-K","ticker":null,"cik":"0001492674","company_name":"T2 Biosystems, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.438898+00:00","generated_at":"2026-05-23T19:34:41.928816+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"T2 Biosystems loses entire board and top management; appoints turnaround specialist as CEO","bullets":["Directors John Sperzel and Robin Toft resigned March 31; Cumming, Elsbree, Toft, Liebman, Adams resigned April 3.","Michael Gibbs resigned as SVP/GC/Secretary March 18; John Sperzel as CEO/President March 31; John Sprague as CFO/Treasurer April 3.","Board appointed Craig Jalbert as CEO, President, Treasurer, Secretary, and Class I director effective April 3, 2025.","Jalbert is a principal at Verdolino & Lowey, P.C., focusing on distressed businesses; compensated $50,000/year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-073558","json":"https://secwatch.observer/filing/0001193125-25-073558.json","markdown":"https://secwatch.observer/filing/0001193125-25-073558.md","text":"https://secwatch.observer/filing/0001193125-25-073558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/d919843d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:34:41.928816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d6ad10f61","claim":"Michael Gibbs resigned as Senior Vice President, General Counsel and Corporate Secretary at T2 Biosystems, Inc..","evidence_excerpt":"On March 18, 2025, Michael Gibbs notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Senior Vice President, General Counsel and Corporate Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President, General Counsel and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"59027d4c3c","claim":"Laura Adams resigned as Director at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5a76ce22b0","claim":"John Sperzel resigned as Chief Executive Officer and President at T2 Biosystems, Inc..","evidence_excerpt":"On March 31, 2025, John Sperzel notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Chief Executive Officer and President.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"8858a79bce","claim":"John W. Cumming resigned as Director at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a8857da18f","claim":"Robin Toft resigned as Director at T2 Biosystems, Inc..","evidence_excerpt":"On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"acdc9497ea","claim":"Seymour Liebman resigned as Director at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b0fb3a2ef8","claim":"David Elsbree resigned as Director at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b7388bb52b","claim":"John Sprague resigned as Chief Financial Officer and Corporate Treasurer at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, John Sprague notified the Company of his resignation from his position as the Company’s Chief Financial Officer and Corporate Treasurer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Corporate Treasurer"}],"fact_type":"executive_change"},{"claim_id":"db2c0a6768","claim":"John Sperzel resigned as Director at T2 Biosystems, Inc..","evidence_excerpt":"On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fa70a95df5","claim":"Craig R. Jalbert was appointed as Class I Director at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"fd4376f079","claim":"Craig R. Jalbert was appointed as Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary at T2 Biosystems, Inc..","evidence_excerpt":"On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}